
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. demonstrates a robust financial trajectory, underscored by sustained growth in its global spine segment, which achieved an impressive 8% revenue growth in the U.S. during the quarter. The company's international orthopedics business showcases incremental progress with 1% growth, while the BGT fracture segment exhibits a solid 4% increase, implying a positive long-term market outlook bolstered by anticipated cross-selling opportunities. Additionally, notable gains in specific spinal product categories indicate strong market share capture, with lateral procedures and minimally invasive lumbar procedures growing by 24% and 18%, respectively, further enhancing the positive growth narrative for the company.
Bears say
Orthofix Medical Inc. exhibited a high GAAP SG&A expense of 72.0% of revenue, exceeding expectations of 66.7%, which reflects operational inefficiencies that may hinder profitability. Additionally, while adjusted EBITDA of $25.1 million surpassed projections, it raises concerns due to an overall lowered revenue forecast of approximately $820 million, reliant on M6 revenue contributions. These financial indicators suggest potential risks and inconsistencies in achieving future growth targets, prompting a cautious outlook on the company’s stock performance.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares